Analysts Issue Forecasts for Soligenix, Inc.’s FY2018 Earnings (SNGX)

Soligenix, Inc. (NASDAQ:SNGX) – Equities research analysts at Zacks Investment Research raised their FY2018 EPS estimates for shares of Soligenix in a report released on Monday, May 14th. Zacks Investment Research analyst G. Zeng now expects that the biopharmaceutical company will post earnings per share of ($1.10) for the year, up from their prior forecast of ($1.49). Zacks Investment Research also issued estimates for Soligenix’s FY2019 earnings at ($1.44) EPS and FY2020 earnings at ($0.89) EPS.

Other research analysts also recently issued reports about the stock. Maxim Group set a $5.00 price objective on shares of Soligenix and gave the company a “buy” rating in a research report on Friday, May 11th. HC Wainwright set a $3.00 price objective on shares of Soligenix and gave the stock a “hold” rating in a research note on Friday, March 16th. Finally, ValuEngine upgraded shares of Soligenix from a “strong sell” rating to a “sell” rating in a research note on Wednesday, May 2nd.

Soligenix stock opened at $1.66 on Wednesday. Soligenix has a fifty-two week low of $1.65 and a fifty-two week high of $1.67.

Soligenix (NASDAQ:SNGX) last released its earnings results on Friday, May 11th. The biopharmaceutical company reported ($0.27) EPS for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.02. Soligenix had a negative net margin of 149.71% and a negative return on equity of 182.10%. The business had revenue of $1.10 million for the quarter.

Soligenix Company Profile

Soligenix, Inc, a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, BioTherapeutics and Vaccines/BioDefense. The BioTherapeutics segment develops SGX301, a photodynamic therapy, which is in Phase III clinical trial to treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that has completed Phase II clinical trial to treat oral mucositis in head and neck cancer.

Receive News & Ratings for Soligenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soligenix and related companies with's FREE daily email newsletter.

Leave a Reply